{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LEXXW"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LEXXW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LEXXW\",,,,,undefined,":{"symbol":"LEXXW","market":"US","secType":"STK","nameCN":"Lexaria Bioscience Corp","latestPrice":0.08,"timestamp":1752696000000,"preClose":0.1647,"halted":0,"volume":19106,"delay":0,"floatShares":5104300,"shares":5104300,"eps":0,"marketStatus":"Pre-Mkt","change":-0.0847,"latestTime":"07-17 07:20:13 EDT","open":0.1616,"high":0.1935,"low":0.08,"amount":2515.3576,"amplitude":0.689132,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1752759000000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.08,"volumeRatio":34.96704814167873},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LEXXW\",,,,,undefined,":{"symbol":"LEXXW","floatShares":5104300,"roa":"-84.74%","roe":"-152.89%","lyrEps":0,"volumeRatio":34.96704814167873,"shares":5104300,"dividePrice":0,"high":0.1935,"amplitude":0.689132,"preClose":0.1647,"low":0.08,"week52Low":0.0685,"pbRate":"0.07","psRate":"0.66","week52High":2,"institutionHeld":0,"latestPrice":0.08,"eps":0,"divideRate":0,"volume":19106,"delay":0,"ttmEps":0,"open":0.1616,"prevYearClose":0.7641,"prevWeekClose":0.1352,"prevMonthClose":0.1,"prevQuarterClose":0.1,"fiveDayClose":0.1497,"twentyDayClose":0.2199,"sixtyDayClose":0.34},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/LEXXW\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LEXXW\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531263682","title":"Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2531263682","media":"ACCESS Newswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531263682?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:15","pubTimestamp":1745871300,"startTime":"0","endTime":"0","summary":"KELOWNA, BC / ACCESS Newswire / April 28, 2025 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering with a single institutional investor for the purchase and sale of 2,000,000 shares of common stock  at a purchase price of $1.00 per share  Other than the pre-funded warrants, no other warrants were issued to the institutional investor in the registered direct offering.H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.The gross proceeds to the Company from the offering were $2.0 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.DehydraTECH is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-announces-closing-2-million-201500135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LEXXW","LEXX","BK4007"],"gpt_icon":0},{"id":"2529293935","title":"LEXX: Second Quarter Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2529293935","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529293935?lang=en_us&edition=fundamental","pubTime":"2025-04-24 17:28","pubTimestamp":1745486880,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience Corporation  reported fiscal second quarter 2025 results through the filing of its Form 10-Q. Since our previous update, the company has made progress with its multiple GLP-1 trials, received patent awards in epilepsy and shared its strategy for advancing its development candidates. Lexaria’s GLP-1-H24-4 trial announced that it had enrolled more quickly than expected and that all five study arms completed enrollment. Results for the study are expected before the end of the year. In this report we will bring investors up to date on the status of Lexaria’s various GLP-1 studies and review second quarter financial performance.General and administrative expenses totaled $1.2 million up 118% from $0.6 million due primarily to higher consulting fees and salaries related to the hiring of a new CEO and CFO, increased legal fees due to additional registration statement filings and greater use of legal advisory services. Greater advertising and promotion expenses were incurred","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexx-second-quarter-results-092800220.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MTA","BK4144","LEXX","BK4007","LEXXW","DHT","BK4188"],"gpt_icon":0},{"id":"2529868706","title":"Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2529868706","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529868706?lang=en_us&edition=fundamental","pubTime":"2025-04-23 21:10","pubTimestamp":1745413800,"startTime":"0","endTime":"0","summary":"Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry. Lexaria's technology could enhance performance and lower side effects. By enhancing the performance of oral dosing choices as a replacement for disliked injections; and by reducing adverse events - often the #1 reason that patients stop using GLP-1 drugs - Lexaria's proprietary DehydraTECH technology could be of vital importance to any of these companies in their pursuit of the next oral GLP-1 drug.Eli Lilly plans to apply for approval to launch the drug for both weight loss and diabetes treatment in 2026 - and that rapid path to market, combined with the fact that it might be only the 2nd oral GLP-1 drug to potentially be approved by the Food and Drug Administration , is likely responsible for the dramatic market response to the news.Although clearly a positive step forward for the weight loss and diabetes treatment sectors, it should still be noted that 13% to 18% of patients receiving the drug ex","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/recent-glp-1-industry-developments-131000677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SGXZ57979304.SGD","BK4599","LU0225284248.USD","IE0002270589.USD","BK4568","LU1894683264.USD","LU0234572021.USD","LU0306807586.USD","LU0321505439.SGD","LU1066053197.SGD","LEXXW","BK4550","LU1066051498.USD","LU1883839398.USD","LU0306806265.USD","LU0122379950.USD","LU1057294990.SGD","SG9999003800.SGD","LU0170899867.USD","LU0058720904.USD","BK4590","BK4592","LU0225771236.USD","LU1894683348.USD","BK4581","IE00B19Z3581.USD","BK4585","BK4144","IE00BLSP4452.SGD","LU1023059063.AUD","SG9999001176.USD","BK4534","LU0321505868.SGD","IE00BBT3K403.USD","IE000M9KFDE8.USD","LU0868494617.USD","SG9999001176.SGD","BK4533","SG9999011175.SGD","SG9999013999.USD","BK4007","IE00B19Z3B42.SGD","LEXX","LU0289739699.SGD","LU0456855351.SGD","SG9999002224.SGD","IE00BLSP4239.USD","LU0985481810.HKD","GLP"],"gpt_icon":1},{"id":"2525906187","title":"We Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth Carefully","url":"https://stock-news.laohu8.com/highlight/detail?id=2525906187","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525906187?lang=en_us&edition=fundamental","pubTime":"2025-04-05 20:13","pubTimestamp":1743855237,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.So, the natural question for Lexaria Bioscience  shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual  free cash flow, which is the amount of money a company spends each year to fund its growth. Let's start with an examination of the business' cash, relative to its cash burn.Lexaria Bioscience's cash burn of US$6.7m is about 27% of its US$25m market capitalisation. That's fairly no","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/think-lexaria-bioscience-nasdaq-lexx-121357902.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SQQQ","LEXX","LU2210149790.SGD","BK4585","TQQQ","BK4007","BK4112","NQmain","LU2095319765.USD","LEXXW","IE00B3QW5Z07.USD","QLD","PSQ",".IXIC","NDAQ","USAW.SI","IE00BKPKM429.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","MNQmain","USJW.SI","TSYW.SI","BK4588","LU2210150020.SGD","NVIW.SI","QID"],"gpt_icon":1}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LEXXW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LEXXW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LEXXW\",market:\"US\",delay:false,,,undefined,":{}}}